Abstract. We previously reported that in the endothelium-denuded rat aorta, lysophosphatidylcholine (LPC) potentiates the contractile responses induced by high-K + , UK14,304 (a selective a 2 -adrenoceptor agonist), and phorbol ester with an associated tyrosine-phosphorylation of proteins. To further investigate this phenomenon, we examined the effects of extracellular-signalregulated protein kinase (ERK)-kinase (MEK) inhibitors on the LPC-induced potentiation of the contractile responses to high-K + and UK14,304 in this tissue. Although PD98059 (3´10 -5 M) did not affect the high-K + -induced contractile response itself, it selectively inhibited the potentiating effect of LPC on the contraction and strongly inhibited the LPC-induced augmentation of the associated increase in [Ca
Introduction
Hypercholesterolemia is a major risk factor for the development of atherosclerotic vascular disease (1) . It has been well established that atherosclerosis is associated with abnormalities of vascular function characterized both by an increase in the response to specific vasoconstrictor agents and by a marked attenuation of endothelium-dependent relaxation (2 -4) . These alterations in vascular reactivity occur at an early stage in the atherosclerotic process and they may predispose arteries to the development of vasospasm. Oxidized low-density lipoprotein (ox-LDL) -a product of endothelial and / or macrophage oxidation of native LDL and present in atherosclerotic lesions -is believed to play an important role in the progression of atherosclerosis (5, 6) and has been shown to impair endothelium-dependent vasorelaxation and to potentiate agonist-induced vasoconstriction (7 -10) . One of the characteristics of ox-LDL is its increased lysophosphatidylcholine (LPC) content. Interestingly, the LPC concentration is many times greater in atherosclerotic arteries than in normal arteries (11) . It has been demonstrated that ox-LDL inhibits endothelium-dependent relaxation in vascular smooth muscle and that the LPC generated during the oxidative modification of LDL is the main factor in the impairment of endothelium-dependent relaxation (12, 13) . Current evidence suggests that LPC inhibits the endothelium-dependent relaxations that are mediated by endothelium-derived relaxing factor (EDRF) and endothelium-derived hyperpolarizing factor (EDHF), and it is likely that LPC causes vascular spasm (13 -15) . In addition, we found in the endothelium-denuded rat aorta that while LPC did not itself produce contraction, it did potentiate the vascular contractile responses induced by high-K + , UK14,304 (5-bromo-6-[2-imidazolin-2-ylamino]-quinoxaline) (a selective a 2 -adrenoceptor agonist), and phorbol ester (16, 17) . Moreover, we recently reported that the potentiating effect of LPC is accompanied by an increase in the tyrosine-phosphorylation of proteins and that both genistein and tyrphostin B42 attenuated the potentiating effect of LPC on high-K + -induced contractions (18) . Although we thought that this LPC effect might be due to an increase in tyrosinekinase activity, the underlying mechanism is still imperfectly understood.
Extracellular-signal-regulated protein kinase (ERK), a subfamily of the mitogen-activated protein kinases (MAPK), has been implicated in a wide range of cellular functions, including proliferation, migration and survival (19) . Activation of ERK is dependent on the dual phosphorylation of threonine and tyrosine by ERK kinases (MAPK/ ERK kinase, MEK) (20) . Recently, it has been shown that ERK also regulates contraction in vascular smooth muscle. G-protein-coupled agonists, such as angiotensin-II, noradrenaline (NA), and 5-hydroxytryptamine (5-HT) are able to activate ERK, and the vasocontraction induced by these G-proteincoupled agonists is inhibited by PD98059 (2'-amino-3'-methoxyflavone), a selective MEK inhibitor (21 -23) .
LPC has a mitogenic effect and it may activate ERK in vascular smooth muscle cells (24) . Moreover, it has been reported that ERK-activation is often an event downstream of protein tyrosine kinase (25) . Because of our previous suggestion that tyrosine-kinase activation is involved in the augmentation by LPC of contractions in the rat aorta (18), we suspected that ERK-activation might play a role in this augmentation effect of LPC. The aim of the present study was to investigate whether the enhancing effect of LPC on contractile responses in the rat aorta might be directly related to ERK-activation.
Materials and Methods

General
This study was conducted in accordance with the Guiding Principles for the Care and Use of Laboratory Animals approved by The Japanese Pharmacological Society.
Preparation of aortic strips
Male Wistar rats, 8 -10-week-old, were anaesthetized with ether and then killed by decapitation. The thoracic aorta was rapidly dissected out and placed into modified Krebs-Henseleit solution (KHS) of the following composition: 118 mM NaCl, 4.7 mM KCl, 1.8 mM CaCl 2 , 25.0 mM NaHCO 3 , 1.2 mM MgSO 4 , 1.2 mM NaH 2 PO 4 , 11.0 mM dextrose). It was then cleaned of loosely adhering fat and connective tissue and cut into helical strips 2 mm in width and 20 mm in length. The endothelium was removed by rubbing the intimal surface with a cotton swab, successful removal being functionally confirmed by the absence of a relaxation to 10 m M acetylcholine.
ERK kinase inhibitors and vascular contraction
Each aortic strip was suspended in an organ bath containing 10 ml of well-oxygenated (95% O 2 + 5% CO 2 ) KHS at 37°C. The contractile responses were measured with the aid of a force-displacement transducer (TB-611; Nihon Kohden, Tokyo) and displayed on a pen recorder (Model 3021; Yokogawa, Tokyo). After the resting tension in each aortic strip was adjusted to 1 g, which was found to be the optimal tension for inducing a maximal contraction in preliminary experiments, the strip was contracted by 80 mM K + , this response being taken as 100%. After washing and equilibrating for 1 h, the aortic strips were treated with one of the ERK kinase (MEK) inhibitors for 20 min and then incubated with LPC for 15 min. After the incubation period, high-K + or UK14,304 was cumulatively applied.
Western blot analysis
Endothelium-denuded aortic tissues were suspended in an organ bath and incubated with 10 -5 M LPC for 15 min. After incubation, the preparations were exposed to 15 mM K + for 10 min. For experiments with inhibitors, tissues were pretreated with genistein, PD98059, or nicardipine for 20 min before the addition of LPC. As a positive control for ERK activation, some aortic tissues were treated with 3´10 -3 M sodium orthovanadate (SOV) for 10 min. These tissues were removed rapidly from the organ bath and rinsed with ice-cold Ca
2+
-free KHS containing 1 mM SOV and 5 mM ethylenediaminetetraacetic acid (EDTA). They were then frozen in liquid N 2 and physically crushed to a fine powder in liquid N 2 using a Cryo-Press (Microtech Nichion, Chiba). These powder samples were mixed into ice-cold sucrose buffer (250 mM sucrose, 10 mM Tris HCl, pH 7.5, 5 mM EDTA, 1 mM 4-(2-aminoethyl)benzenesulphonyl fluoride hydrochloride (AEBSF), 10 mg/ ml aprotinin, 10 m g / ml leupeptin, 1 mM SOV, 10 mM NaF, 0.1% triton X-100) and then centrifuged at 14,000´g for 20 min at 4°C. The supernatant was collected and its protein concentration measured by means of the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL, USA), with bovine serum albumin (BSA) as a standard. These sample proteins were solubilized in Laemmli buffer and boiled for 5 min at 90°C. Equal amounts of proteins (3 m g) were separated by electrophoresis on 10% sodium dodecyl sulphate (SDS)-polyacrylamide gel and electrically transferred to a polyvinylidene difluoride membrane. The membrane was washed with Tris-buffered saline containing 0.1% Tween-20 (TBS-T) and then blocked by an overnight incubation at 4°C in TBS-T containing 3% non-fat dry milk. After washing in TBS-T, the membrane was incubated with rabbit polyclonal phospho-p44 / 42 MAP kinase (Thr 202 / Tyr 204 ) antibody (1:2000) for 1 h, washed again with TBS-T, and then incubated with horseradishperoxidase-conjugated goat anti-rabbit secondary antibody (1:4000) for 1 h. After a final wash with TBS-T, antibody-binding was visualized using an ECL-plus Western blotting detection system (Amersham Pharmacia Biotech, Uppsala, Sweden). Developed films were scanned and analyzed using an NIH Image program.
Total ERK was measured in the same membranes after stripping the antibodies by incubating the membranes in Re-blot solution (Chemicon Co., Temecula, CA, USA). After blocking, the membranes were incubated with rabbit polyclonal p44 / 42 MAP kinase antibody (1:2000) for 1 h and then examined as described above.
Measurement of intracellular free Ca
2+ and tension
Simultaneous recordings of contractile tension and [Ca
2+
] i in the same tissue were made as described previously (16) . Briefly, aortic strips were exposed to 10 -5 M fura PE3-acetoxymethyl ester (fura PE3-AM) in the presence of 0.04% Cremophor EL in the dark for 5 h at 26°C. The tissue was then rinsed with normal KHS and placed in the organ bath of a fluorometer (CAF110; Japan Spectroscopic, Tokyo) containing KHS at 37°C. The intimal surface of the fura-PE3-loaded tissue was alternately subjected to excitation wavelengths of 340 and 380 nm. The fluorescence emissions at a wavelength of 500 nm for each excitation light were separated by means of a dichroic mirror and then measured with the aid of a photomultiplier. The ratio (F340 / F380) of the emitted fluorescence signals was used to provide an index of [Ca
] i . The contractile responses and the emitted fluorescence signals were displayed on a pen recorder (Model 3021, Yokogawa).
After equilibration, each aortic strip was first exposed to 80 mM K + . The fluorescence ratio (F340 / F380) in the resting muscle and that in muscle depolarized by 80 mM K + were taken as 0 and 100%, respectively. After washing, the aortic strips were first treated with LPC for 15 min and then high-K + or UK14,304 was applied.
Drugs
The drugs used (and their suppliers) were as follows: AEBSF, aprotinin, Cremophor EL, EDTA, genistein, leupeptin, L-a -lysophosphatidylcholine (palmitoyl), NaF, nicardipine, SOV, triton X-100, UK14,304 (Sigma Chemical Co., St. Louis, MO, USA); acetylcholine (Daiichi Pharmaceuticals Co., Tokyo); fura PE3-AM (Wako Pure Chemical Industries Ltd., Osaka); PD98059 ] i or tension in the aortic strips. Genistein, nicardipine, PD98059, U0124, U0126, and UK14,304 were dissolved in DMSO and diluted as required in distilled water. AEBSF was dissolved in ethanol and diluted as required in distilled water. All other drugs were dissolved in distilled water.
Statistics
The results shown in the text and Figures are expressed as the mean ± S.E.M. Statistical differences were assessed by Dunnett's multiple-comparison test following a one-way analysis of variance (ANOVA). Statistical comparisons between concentration-response curves were made using a two-way ANOVA, with the Bonferroni correction performed post hoc to correct for multiple comparisons. Values for 50% effective concentration (EC 50 ) were obtained by linear regression analysis and are expressed as pD 2 value (-log EC 50 ). For Westen blot analysis, data were normalized with respect to the positive control (obtained from 3 mM SOVtreated tissue) for each film, and the increase in the phosphorylation of ERK was quantified using the value obtained by expressing the amount of phosphorylated ERK (p-ERK) as a percentage of total ERK (% p-ERK / ERK) as the index.
Results
Effects of ERK-kinase inhibitors on high-K + -and UK14,304-induced contractions in the presence of LPC LPC (10 -5 M) did not itself produce a contraction, but it did significantly potentiate the high-K + -induced contraction, the effect being most marked at 10 -20 mM (Fig. 1A) . The pD 2 value for high-K + was significantly greater in the presence of LPC (Table 1) ; however, LPC did not affect the maximal response. Although PD98059, an ERK-kinase (MEK) inhibitor (21 -23), did not, at a concentration of 3´10 -5 M, inhibit the high-K + -induced contraction, it abolished the potentiating effect of LPC on this contraction (Fig. 1B) . The presence of 3´10 -5 M PD98059 did not significantly alter the pD 2 values for high-K + obtained in the presence or absence of LPC. Lower concentrations of PD98059 (3´10 -6 M, 10 -5 M) also attenuated the LPC-effect in a dose-related manner (Fig. 1C) . Figure 1D shows the effect of U0126, another ERK-kinase inhibitor (26) , on the LPC-induced potentiation of the high-K + -induced contraction. At a concentration of 5´10 -5 M, it inhibited the high-K + -induced contraction and abolished the potentiating effect of LPC. On the other hand, the inactive analogue U0124 did not attenuate the LPC-effect (data not shown).
LPC potentiated the UK14,304-induced contraction more effectively than the high-K + -induced contraction ( Fig. 2A and Table 1 ). Unlike the high-K + -induced contraction, the UK14,304-induced contraction was itself dose-dependently inhibited by PD98059 (3´10 -6 to 3´10 -5 M) ( Fig. 2 : B, C, D and Table 1 ). The enhancement effect of LPC on the UK14,304-induced contraction was also dose-dependently inhibited by PD98059 (Fig. 2 : B, C, D and Table 1 ).
LPC-induced ERK-phosphorylation
The above results suggested that ERK-activation might be involved in the augmentation effects produced by LPC on contractile responses in the rat aorta because both PD98059 and U0126 are selective inhibitors of ERK kinase (MEK), which is the upstream activator of ERK (20) . We therefore set out to investigate whether LPC did indeed induce ERK-phosphorylation (by means of Western blot analysis using phospho-p44 / 42 MAPK antibody and p44 / 42 MAPK antibody). Figure 3 (A  and B) shows the changes in muscle-tension development Values represent the mean ± S.E.M. from 4 -7 muscle preparations, each isolated from a different animal. N.T. = not tested. **P<0.01 vs control value (without LPC). produced an enhanced contractile response in association with a level of ERK phosphorylation similar to that seen with LPC alone. Genistein (10 -5 M) inhibited both the increase in ERK-phosphorylation and the augmentation effect on the contractile response that were induced by LPC. The amount of total ERK was similar among the various conditions (Fig. 3B) . Like genistein, PD98059 inhibited both the increase in ERKphosphorylation and the augmentation effect on the contractile response that were induced by LPC (Fig. 4) . In the case of PD98059, both of the parameters examined were inhibited dose-dependently, and the reductions occurred more or less in parallel.
Effects of PD98059 on changes in cytosolic Ca
2+ associated with high-K + -and UK14,304-induced contractions in the presence of LPC Figure 5 shows the changes in tension development and cytosolic free Ca ] i and tension in a dose-related manner (Fig. 5B) . LPC (10 -5 M) markedly augmented these increases. PD98059 (10 -5 M) not only inhibited the UK14,304-induced responses but also strongly attenuated the augmentation produced by LPC.
Effects of nicardipine on LPC-induced ERK-phosphorylation
Nicardipine inhibited the contraction induced by 15 mM K + in the LPC-treated aorta in a dose-dependent manner, and higher concentrations of nicardipine nearly abolishing the response (Fig. 6) . However, these concentrations of nicardipine did not significantly inhibit the increase in ERK-phosphorylation induced by LPC.
Finally, we examined whether high-K + -induced depolarization caused an increase in ERK-phosphorylation. Treatment with high-K + , at a concentration from within the range of 15 -120 mM, produced a contraction in a dose-dependent manner (Fig. 7) , treatment with 40 mM K + inducing a sub-maximal response. In contrast, treatment with 15 -40 mM K + did not increase ERK-phos- phorylation, 80 or 120 mM K + being needed to cause a detectable increase.
Discussion
In the present study, we demonstrated that ERK-activation is induced by LPC in the endothelium-denuded rat aorta and that the ERK-pathway may play a key role in the potentiating effect of LPC on the contractions induced by high-K + and UK14,304. MAPK-cascades transmit and amplify signals involved in cell proliferation, migration and survival (19, 27) . MAPK comprises a family of serine / threonine kinases, which includes ERK, c-jun N-terminal kinase (JNK), and p38-MAPK. These signal-transduction pathways serve as intracellular messengers for the effects induced by various growth factors, steroid hormones, and ligands via G-protein-coupled receptors. Of these MAPKs, ERK has been reported also to modulate smooth muscle contractility. Zheng et al. (28) reported that the epidermal growth factor (EGF) urogastrone-induced contraction in guinea pig gastric smooth muscle is sensitive to PD98059. Moreover, angiotensin II, NA, and 5-HT all activate ERK, and the ERK-pathway modulates the effects of these vasoconstrictors on vascular smooth muscle (21 -23) . Recently, Roberts (29) reported that the vasoconstriction induced by the a 2 adrenoceptor agonist UK14,304 in the porcine palmar lateral vein is dependent upon activation of the ERK-signal-transduction cascade. In the present study, the finding that PD98059 markedly attenuated the increases in [Ca 2+ ] i and tension induced by UK14,304 in the rat aorta without affecting the responses induced by high-K + suggests that UK14,304-induced contractile responses may be regulated via the ERK-pathway.
The major findings made in the present study were that LPC potentiated the contractile responses induced in the rat aorta by both high K + and UK14,304 and also potentiated the associated ERK-activation. The augmentation effect produced by LPC on the high-K + -induced contraction was concentration-dependently inhibited by PD98059, as was the LPC-induced potentiation of the contractile response to UK14,304. Western blot analysis showed that LPC produced an increase in ERKphosphorylation and that the ERK-phosphorylation was inhibited by PD98059 at a concentration that also attenuated the LPC-induced potentiation of the contractile responses. These results suggest that an increase in ERK activity may be involved in the LPC-induced augmentation of contractile responses in the rat aorta. The involvement of ERK is supported by the observed effects of U0126 (another ERK-kinase inhibitor). In the present study, LPC did not potentiate the high-K + -induced contraction seen in the presence of U0126. We previously reported that LPC increased the tyrosinephosphorylation of a number of proteins and that these protein-phosphorylations were inhibited by genistein (18) . In the present study, genistein also inhibited the LPC-induced ERK-phosphorylation. Taken together, these results suggest that LPC may stimulate the tyrosine-kinase ERK pathway and thereby modulate contractile responses in the rat aorta.
The mechanisms by which ERK regulates contraction are still unclear. Some recent studies suggested that activation of ERK increases the phosphorylation of caldesmon, which in turn modulates the Ca 2+ sensitivity of the contractile apparatus (30, 31) , whereas another study suggested that ERK plays a role in the regulation of [Ca 2+ ] i in vascular smooth muscle (32 ] i induced by LPC remains unclear. It is generally accepted that the ERKactivation mediated by G-protein-coupled receptors is Ca 2+ -, calmodulin-, Pyk2-, and Src-tyrosine-kinasedependent (25) . It has been reported that the L-type Ca
2+
-channel blocker, nicardipine, inhibited a 2 -adrenoceptor-mediated ERK-phosphorylation in the porcine palmar lateral vein (29) . In contrast, in cultured cells, EGF has been reported to mediate ERK-activation via a Ca 2+ / calmodulin-independent mechanism (25) . In the present study, the high-K + -induced contractile response seen in the LPC-treated aorta was concentration-dependently inhibited by nicardipine. However, our Western blot analysis revealed that the LPC-induced increase in ERK-phosphorylation was not inhibited by nicardipine at a concentration that did attenuate the contractile response. These results suggest that in the rat aorta, LPC-induced ERK-activation may not be dependent on (23, 33, 34) . In the present study, high-K + , at concentrations of 80 and 120 mM, proved able to phosphorylate ERK in the rat aorta. However, lower concentrations of K + (15 -40 mM) failed to have this effect. In particular, application of 40 mM K + , which produced a sub-maximal contraction, did not significantly increase ERK-phosphorylation. Moreover, the concentration-response curves for high-K + showed no evidence of inhibition by PD98059. These results suggest that while a strong depolarization induced by higher concentrations of K + might mediate ERK-activation, activation of this kinase by high-K + is not essential for contraction. Our findings also suggest that LPC does not modulate the ERK-activation induced by these vasoconstrictors, but that it may activate ERK via an individual pathway. Our present findings suggest the conclusion that LPC alone may be sufficient to increase ERK-phosphorylation, and indeed, this increase did not appear to be any less than that induced by LPC plus high-K + . In atherosclerosis, ox-LDL accumulates in the vascular wall (5, 6) . Since LPC accumulates in ox-LDL and in atherosclerotic arteries (11, 35) , we speculate that it may modulate vascular tone via an ERK-pathway in concert with its inhibitory effect on endotheliumdependent arterial relaxation.
In conclusion, this study confirms previous observations that the LPC-induced augmentation of contractile responses in the rat aorta is due to activation of tyrosine kinase, and it adds the novel observation that ERKkinase (MEK) inhibitors attenuated this effect of LPC. Moreover, LPC produced an increase in ERK-phosphorylation, an effect inhibited by PD98059. Hence, the augmentation effect of LPC in the rat aorta may involve ERK-activation and a consequent regulation of Ca 2+ influx.
